1. Home
  2. UPXI vs PYPD Comparison

UPXI vs PYPD Comparison

Compare UPXI & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Upexi Inc.

UPXI

Upexi Inc.

HOLD

Current Price

$0.89

Market Cap

61.8M

Sector

Health Care

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$3.74

Market Cap

71.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UPXI
PYPD
Founded
2018
2008
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.8M
71.7M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
UPXI
PYPD
Price
$0.89
$3.74
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$2.00
$12.25
AVG Volume (30 Days)
1.2M
338.2K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
92.49
N/A
EPS
N/A
N/A
Revenue
$15,811,345.00
N/A
Revenue This Year
$118.99
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$3.06
52 Week High
$9.12
$5.73

Technical Indicators

Market Signals
Indicator
UPXI
PYPD
Relative Strength Index (RSI) 50.59 36.07
Support Level $0.85 $3.50
Resistance Level $0.93 $4.44
Average True Range (ATR) 0.06 0.43
MACD 0.01 -0.17
Stochastic Oscillator 79.36 4.81

Price Performance

Historical Comparison
UPXI
PYPD

About UPXI Upexi Inc.

Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: